22nd ECNP Congress 2009: are the Monoamines Involved in Shaping Conduct Disorders?ISTANBUL, Turkey - New findings on the significance of platelet MAO activity and MAO gene variants with regard to antisocial behaviour have today been presented by Prof. Lars Oreland, University of Uppsala, Sweden, at a press conference during the 22nd ECNP Congress. Prof. Oreland outlined that, based on gene-environment interactions, the brain monoamine systems play a crucial role in shaping personality traits and conduct disorder. The monoamine oxidases (MAOs) genes appear to be the first genes strongly linked with either antisocial behaviour or conduct disorder. Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San FranciscoPARIS - Novexel, a specialty pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its pipeline will be the subject of 16 posters and one slide presentation at the 49th annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The ICAAC meeting, which is taking place in San Francisco, California, September 12-15 2009, is the leading global conference on anti-microbial agents globally with over 10,000 participants. Instanyl(R) (intranasal fentanyl spray) Sets New Standard in Management of Breakthrough Cancer PainLISBON, Portugal - - Head to Head Study Confirms Superiority of the New Intranasal Treatment for Breakthrough Cancer Pain Over OTFC New Data From CLARITY Study on Disease Activity in MS Patients who Received Cladribine Tablets Presented at 25th ECTRIMS CongressDÜSSELDORF, Germany and GENEVA - - Post-hoc Analysis From CLARITY Study Show That Short-Course Oral Treatment With Cladribine Tablets Significantly Increased the Proportion of Patients who had Absence of Disease Activity Compared With Placebo ThromboGenics is Shortlisted for “Biotech Company of the Year” and “Licensing Deal of the Year” at Scrip Awards 2009LEUVEN, Belgium - - ThromboGenics’ Significant Achievements Over the Last Year are Recognised in Nominations Life Sciences Vital for Economic RecoveryLONDON - The Association of British Pharmaceutical Industry (ABPI) will be launching their manifesto ‘Prescription for Innovation’ on Monday 14 September at Imperial College. The manifesto will be launched by Chris Brinsmead, President of the ABPI, in partnership with Richard Lambert of the CBI, Professor Steve Smith of Imperial and Ade Adeagbo of patients’ organisation National Voices. Results From Improve Study Show MRI Benefits of Rebif(R) Seen Early in Relapsing-Remitting Multiple Sclerosis Treatment and Sustained Over TimeGENEVA - - Data Presented at the 25th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) Held in Dusseldorf, Germany, From September 9-12, 2009. New Research Indicates 95% of Patients are in Moderate to Severe Chronic Pain Despite One Year of TreatmentEUROPEAN FEDERATION OF CHAPTERS OF THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF PAIN (EFIC) CONGRESS, LISBON - Milliman Estimates Impact of Swine Flu on Employer Revenue and ProfitsLONDON - Modelling carried out by Milliman actuaries estimates that a severe swine flu pandemic has the potential to reduce a typical UK employer’s revenue by 4%-5% and its profit rate by five to six percentage points during the quarter of the pandemic. Dutch Top Institute Pharma Attracts International InterestLEIDEN, The Netherlands - The Danish Council for Strategic Research is visiting the Dutch Top Institute Pharma (TI Pharma) on Thursday, September 10. The purpose of their visit is to learn about the unique Dutch approach on public-private cooperation and the concrete results that are being booked by this institute. In the past, in the European Council, Denmark has cited TI Pharma as a prime example of public-private collaboration in the pharmaceutical sector and is considering following its lead. arGEN-X Raises EUR9.5 Million to put SIMPLE Antibody(TM) Platform to WorkROTTERDAM, The Netherlands - arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody(TM) platform, today announced the successful first closing of its Series A equity financing round. The Company raised EUR 9.5million (~ USD 13.6 million) from a syndicate of leading life science investors. The financing round is one of the largest of its kind in the last 12 months. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio StrategyOXFORD, England - PharmaVentures announced today the appointment of Nikki Watkins as Head of the Product & Portfolio Strategy Practice of Corporate Advisory, leading a team of Senior Advisors and Analysts. Pergamum to Provide Effective Development of Innovative Dermatology and Wound Healing CompaniesSTOCKHOLM - Pergamum AB has announced its formation; Pergamum will commercialize the Karolinska Development dermatology and wound healing interests, and create a broad-based therapeutic company in its focus areas. PRA International Chairs Session on Post Marketing Safety IssuesRALEIGH, North Carolina - - PRA Experts Present at the World Drug Safety Congress PRA International, a leading Clinical Research Organization, will chair and present at a session during the Third Annual World Drug Safety Congress to be held in London on 16-17 September, 2009. The Congress is a gathering of leading Safety, Risk Management and Pharmacovigilance professionals. On 16 September, Dr. Sabine Richter, PRA’s Vice President of Safety and Risk Management, will chair a session on Post Marketing Safety Strategy. In this session, Mark Nelson Tyrrell, BS, RPh, Director, Safety and Risk Management at PRA, will present: Post-Marketing Safety Surveillance Design: Choices and Implementation. Helix BioPharma Closes Private PlacementAURORA, Ontario - Helix BioPharma Corp. (TSX, FSE: “HBP”; OTCQX: “HXBPF”) today announced that it has closed its previously announced private placement of 6,625,000 units at US$2.05 per unit. First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer PainLISBON, Portugal - - Choosing a More Appropriate Route of Administration for Fast Acting Pain Relief Could be the key to Improvement New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Group’s American subsidiary, Helsinn Therapeutics (U.S.) Inc.LUGANO, Switzerland - As part of the Helsinn Group’s development strategy, William Mann, PhD, has been appointed as new CEO in the American subsidiary, Helsinn Therapeutics (U.S.) Inc. William Mann, PhD, was already Chief Operating Officer of the recently acquired Helsinn Therapeutics, and has held leadership positions in a Swiss multinational with positions in Business Development and in Research. Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics SectionBRIDGEWATER, England - Clinical Therapeutics,( www.clinicaltherapeutics.com/) the world’s premier, rapid-publication journal, is proud to announce the addition of Michael G. Spigarelli, MD, PhD, to our distinguished editorial board. 2009 India Excellence in Healthcare AwardsMUMBAI, India - - Annual India Excellence in Healthcare Awards to Celebrate Best in the Industry Relaunched Healthcare Republic Provides the Best Online Resources for Primary Care PractitionersLONDON - Users of leading primary care website Healthcare Republic ( www.healthcarerepublic.com/) will now find it easier than ever to find drug and research updates, archived articles and breaking news from all of Haymarket’s medical publications. Karolinska Development Introduces New Concept for Development of its Dermatology and Wound Healing PortfolioSTOCKHOLM - Karolinska Development (publ) have announced the formation of Pergamum AB, a company that will commercialize its dermatology and wound healing opportunities as associated business units within one company. Karolinska Development has transferred all of its holdings from its five dermatology and wound healing companies to Pergamum AB, owning 64% of the new company. Tata Interactive Systems Initiates Vertical-Focused Learning Solutions for Health Care, Pharmaceutical, and BiotechnologyMUMBAI, India - - Tata Interactive Systems Announces its First Domain-Specific Learning and Consulting Solutions for Health Care MitraClip(R) Therapy Introduced in AustriaMENLO PARK, California - - Use of the MitraClip(R) System Continues to Expand in Europe /C O R R E C T I O N — Clinical Therapeutics/BRIDGEWATER, New Jersey - In the news release, “Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section” issued on 9 Sep 2009 08:30 GMT, by Clinical Therapeutics over PR Newswire, we are advised by a representative of the company that the Dateline has been changed from “Bridgewater, England” to “Bridgewater, New Jersey” and the contact number has been changed from +44(0)908-547-2094 to +1-908-547-2094 which were incorrectly transmitted by PR Newswire. Complete, corrected release follows: /C O R R E C T I O N — Nycomed/LISBON, Portugal - In the news release, “First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain” issued on 9 Sep 2009 07:00 GMT, by Nycomed over PR Newswire, we are advised by a representative of the company that the first set of bullet points should read “The median number of BTCP episodes per patient per day was 3; Each episode had a median duration of 60 minutes; 96% of the pain episodes were described as moderate to severe; For 90% of patients their BTCP interfered with their daily living including their ability to sleep, walk and get on with other people” and the second set of bullet points should read “At least 95% of patients were using orally administered drugs; “The time to first noticing a reduction in pain had a median time of 20 minutes; In this survey the median time to peak effect of the current BTCP rescue medications was 30 minutes”. In addition, the fourth paragraph should read “For this kind of pain episode the ideal treatment would be fast acting with a short duration of action to most closely match the nature of BTCP episodes” instead of “For this kind of pain episode the ideal treatment would be fast acting with short duration of action to most closely match the nature of BTCP episodes” as incorrectly transmitted by PR Newswire. Complete, corrected release follows: LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus ChallengeBOZEMAN, Montana - LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will assess safety and immunogenicity associated with LigoCyte’s investigational, nasally-delivered, dry powder vaccine in healthy adults. The study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received either the vaccine or placebo. Clinical studies to date have shown the vaccine to be immunogenic and generally well tolerated in human subjects. Update on Velaglucerase AlfaCAMBRIDGE, Massachusetts - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, is committed to doing everything possible to assist Gaucher patients and their physicians during the imiglucerase supply shortage. Shire is pleased to be able to provide velaglucerase alfa well over a year ahead of previously anticipated commercial launch world wide. 50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY(SM)COLUMBUS, Ohio - - Novel analgesic marks major milestone in scientific discovery Chemical Abstracts Service (CAS) (www.cas.org/), a division of the American Chemical Society, announced that on September 7 it recorded the 50 millionth substance in CAS REGISTRY, the world’s most comprehensive and high-quality compendium of publicly disclosed chemical information. The recently registered substance is a novel arylmethylidene heterocycle with analgesic properties. Reaching the 50 million mark so quickly is an indicator of the accelerating pace of scientific knowledge. CAS registered the 40 millionth substance just nine months ago - in contrast, it took 33 years for CAS to register the 10 millionth compound in 1990. Founder of Curidium Launches Elixior, an Advisory Company Focused on the Development and Growth of Innovative Personalized Medicine BusinessesLONDON - Elixior Limited, the advisory company focused on the development and growth of innovative personalized medicine businesses, announced today its launch by the founder and former CEO of Curidium, Dr Anne Bruinvels. OAG Releases Prototype for Pandemic Disease Planning and ManagementCHICAGO - - Modelling Air Travel Could Prove Critical for Health Organizations and Government Agencies Preparing for the Upcoming Flu Season REGURIN(R) XL (trospium chloride) Once Daily Tablets Now Available in the UK for the Treatment of Overactive BladderLONDON - Regurin(R) XL (trospium chloride), a once-daily, prolonged-release capsule to treat patients with overactive bladder (OAB) has been launched in the UK. Regurin(R) XL provides rapid, significant and consistent improvements in the symptoms of OAB1 and has a reduced potential for central nervous system (CNS) side effects(2-7). Tosho’s Satisfaction With Health Robotics Steers the Japanese Pharmacy Automation Leader to Renew and to Expand its I.V. Automation Strategic PartnershipBOZEN, Sud-Tyrol, Italy - Health Robotics today announced that after a successful first year of cooperation in Japan with Tosho Inc., the companies signed this week a contract renewal of the CytoCare(TM) and i.v.STATION(TM) exclusive distribution agreements, and an expansion of their strategic relationship to include future joint-development projects in their respective areas of Pharmacy Automation expertise. SYGNIS to Present at the 11th Rodman & Renshaw Annual Global Investment ConferenceHEIDELBERG, Germany - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) announced today that the company will present at the 11th Rodman & Renshaw Annual Global Investment Conference, September 9-11, 2009 at the New York Palace Hotel, New York. The presentation will be given by Prof. Karoly Nikolich, CEO of the SYGNIS subsidiary Amnestix Inc. on September 11, 2009 at 2:25 p.m. EDT (20:25 CET) in the Garrison Salon. Home-Spun or Hard Fact?NEWBURY, England - - Fast-Food Family Planning May Contribute to High Levels of Unintended Pregnancies Helix BioPharma Announces CDN$13.5 Million Private PlacementAURORA, Ontario - Helix BioPharma Corp. (TSX, FSE: “HBP” / OTCQX: “HXBPF”) today announced that it has accepted subscriptions for the purchase, by way of private placement, of a total of 6,625,000 units at CDN$2.05 per unit, for gross proceeds totaling CDN$13,581,250. The Company anticipates closing the private placement by September 11, 2009. |
